Title |
Efficacy of thiopurines and adalimumab in preventing Crohn's disease recurrence in high‐risk patients – a POCER study analysis
|
---|---|
Published in |
Alimentary Pharmacology & Therapeutics, August 2015
|
DOI | 10.1111/apt.13353 |
Pubmed ID | |
Authors |
P De Cruz, M A Kamm, A L Hamilton, K J Ritchie, E O Krejany, A Gorelik, D Liew, L Prideaux, I C Lawrance, J M Andrews, P A Bampton, S Jakobovits, T H Florin, P R Gibson, H Debinski, R B Gearry, F A Macrae, R W Leong, I Kronborg, G Radford-Smith, W Selby, M J Johnston, R Woods, P R Elliott, S J Bell, S J Brown, W R Connell, P V Desmond |
Abstract |
Crohn's disease recurs in the majority of patients after intestinal resection. To compare the relative efficacy of thiopurines and anti-TNF therapy in patients at high risk of disease recurrence. As part of a larger study comparing post-operative management strategies, patients at high risk of recurrence (smoker, perforating disease, ≥2nd operation) were treated after resection of all macroscopic disease with 3 months metronidazole together with either azathioprine 2 mg/kg/day or mercaptopurine 1.5 mg/kg/day. Thiopurine-intolerant patients received adalimumab induction then 40 mg fortnightly. Patients underwent colonoscopy at 6 months with endoscopic recurrence assessed blind to treatment. A total of 101 patients [50% male; median (IQR) age 36 (25-46) years] were included. There were no differences in disease history between thiopurine- and adalimumab-treated patients. Fifteen patients withdrew prior to 6 months, five due to symptom recurrence (of whom four were colonoscoped). Endoscopic recurrence (Rutgeerts score i2-i4) occurred in 33 of 73 (45%) thiopurine vs. 6 of 28 (21%) adalimumab-treated patients [intention-to-treat (ITT); P = 0.028] or 24 of 62 (39%) vs. 3 of 24 (13%) respectively [per-protocol analysis (PPA); P = 0.020]. Complete mucosal endoscopic normality (Rutgeerts i0) occurred in 17/73 (23%) vs. 15/28 (54%) (ITT; P = 0.003) and in 27% vs. 63% (PPA; P = 0.002). The most advanced disease (Rutgeerts i3 and i4) occurred in 8% vs. 4% (thiopurine vs. adalimumab). In Crohn's disease patients at high risk of post-operative recurrence adalimumab is superior to thiopurines in preventing early disease recurrence. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 5 | 38% |
United Kingdom | 2 | 15% |
Australia | 1 | 8% |
Spain | 1 | 8% |
Brazil | 1 | 8% |
Unknown | 3 | 23% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 10 | 77% |
Scientists | 2 | 15% |
Practitioners (doctors, other healthcare professionals) | 1 | 8% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | <1% |
Chile | 1 | <1% |
Unknown | 144 | 99% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 18 | 12% |
Student > Doctoral Student | 16 | 11% |
Other | 15 | 10% |
Student > Bachelor | 11 | 8% |
Student > Ph. D. Student | 11 | 8% |
Other | 40 | 27% |
Unknown | 35 | 24% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 86 | 59% |
Psychology | 5 | 3% |
Biochemistry, Genetics and Molecular Biology | 4 | 3% |
Nursing and Health Professions | 4 | 3% |
Pharmacology, Toxicology and Pharmaceutical Science | 3 | 2% |
Other | 7 | 5% |
Unknown | 37 | 25% |